Literature DB >> 20032461

Control of steroid 21-oic acid synthesis by peroxisome proliferator-activated receptor alpha and role of the hypothalamic-pituitary-adrenal axis.

Ting Wang1, Yatrik M Shah, Tsutomu Matsubara, Yueying Zhen, Tomotaka Tanabe, Tomokazu Nagano, Serge Fotso, Kristopher W Krausz, T Mark Zabriskie, Jeffrey R Idle, Frank J Gonzalez.   

Abstract

A previous study identified the peroxisome proliferator-activated receptor alpha (PPARalpha) activation biomarkers 21-steroid carboxylic acids 11beta-hydroxy-3,20-dioxopregn-4-en-21-oic acid (HDOPA) and 11beta,20-dihydroxy-3-oxo-pregn-4-en-21-oic acid (DHOPA). In the present study, the molecular mechanism and the metabolic pathway of their production were determined. The PPARalpha-specific time-dependent increases in HDOPA and 20alpha-DHOPA paralleled the development of adrenal cortex hyperplasia, hypercortisolism, and spleen atrophy, which was attenuated in adrenalectomized mice. Wy-14,643 activation of PPARalpha induced hepatic FGF21, which caused increased neuropeptide Y and agouti-related protein mRNAs in the hypothalamus, stimulation of the agouti-related protein/neuropeptide Y neurons, and activation of the hypothalamic-pituitary-adrenal (HPA) axis, resulting in increased adrenal cortex hyperplasia and corticosterone production, revealing a link between PPARalpha and the HPA axis in controlling energy homeostasis and immune regulation. Corticosterone was demonstrated as the precursor of 21-carboxylic acids both in vivo and in vitro. Under PPARalpha activation, the classic reductive metabolic pathway of corticosterone was suppressed, whereas an alternative oxidative pathway was uncovered that leads to the sequential oxidation on carbon 21 resulting in HDOPA. The latter was then reduced to the end product 20alpha-DHOPA. Hepatic cytochromes P450, aldehyde dehydrogenase (ALDH3A2), and 21-hydroxysteroid dehydrogenase (AKR1C18) were found to be involved in this pathway. Activation of PPARalpha resulted in the induction of Aldh3a2 and Akr1c18, both of which were confirmed as target genes through introduction of promoter luciferase reporter constructs into mouse livers in vivo. This study underscores the power of mass spectrometry-based metabolomics combined with genomic and physiologic analyses in identifying downstream metabolic biomarkers and the corresponding upstream molecular mechanisms.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20032461      PMCID: PMC2844213          DOI: 10.1074/jbc.M109.090175

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  43 in total

Review 1.  Peroxisome proliferator-activated receptors: nuclear control of metabolism.

Authors:  B Desvergne; W Wahli
Journal:  Endocr Rev       Date:  1999-10       Impact factor: 19.871

2.  Isolation and identification of four new carboxylic acid metabolites of cortisol in man.

Authors:  H L Bradlow; B Zumoff; C Monder; H J Lee; L Hellman
Journal:  J Clin Endocrinol Metab       Date:  1973-11       Impact factor: 5.958

3.  Involvement of the peroxisome proliferator-activated receptor alpha in the immunomodulation caused by peroxisome proliferators in mice.

Authors:  Qian Yang; Yi Xie; Stefan E H Alexson; B Dean Nelson; Joseph W DePierre
Journal:  Biochem Pharmacol       Date:  2002-05-15       Impact factor: 5.858

4.  Regulated expression by PPARalpha and unique localization of 17beta-hydroxysteroid dehydrogenase type 11 protein in mouse intestine and liver.

Authors:  Yasuhide Yokoi; Yuka Horiguchi; Makoto Araki; Kiyoto Motojima
Journal:  FEBS J       Date:  2007-08-21       Impact factor: 5.542

5.  Tissue distribution, ontogeny, and regulation of aldehyde dehydrogenase (Aldh) enzymes mRNA by prototypical microsomal enzyme inducers in mice.

Authors:  Yazen Alnouti; Curtis D Klaassen
Journal:  Toxicol Sci       Date:  2007-11-12       Impact factor: 4.849

6.  Selectivity determinants of inhibitor binding to human 20alpha-hydroxysteroid dehydrogenase: crystal structure of the enzyme in ternary complex with coenzyme and the potent inhibitor 3,5-dichlorosalicylic acid.

Authors:  Urmi Dhagat; Satoshi Endo; Rie Sumii; Akira Hara; Ossama El-Kabbani
Journal:  J Med Chem       Date:  2008-07-12       Impact factor: 7.446

7.  Specificity of hepatic aldehyde dehydrogenase inhibition by calcium carbimide (calcium cyanamide) in the rat.

Authors:  C W Loomis; J F Brien
Journal:  Can J Physiol Pharmacol       Date:  1983-04       Impact factor: 2.273

8.  Tissue-specific induction of 17 beta-hydroxysteroid dehydrogenase type IV by peroxisome proliferator chemicals is dependent on the peroxisome proliferator-activated receptor alpha.

Authors:  L Q Fan; R C Cattley; J C Corton
Journal:  J Endocrinol       Date:  1998-08       Impact factor: 4.286

9.  PPARalpha is a key regulator of hepatic FGF21.

Authors:  Thomas Lundåsen; Mary C Hunt; Lisa-Mari Nilsson; Sabyasachi Sanyal; Bo Angelin; Stefan E H Alexson; Mats Rudling
Journal:  Biochem Biophys Res Commun       Date:  2007-06-21       Impact factor: 3.575

10.  Hepatic glucose sensing via the CREB coactivator CRTC2.

Authors:  Renaud Dentin; Susan Hedrick; Jianxin Xie; John Yates; Marc Montminy
Journal:  Science       Date:  2008-03-07       Impact factor: 47.728

View more
  11 in total

1.  Metabolomics reveals an essential role for peroxisome proliferator-activated receptor α in bile acid homeostasis.

Authors:  Fei Li; Andrew D Patterson; Kristopher W Krausz; Naoki Tanaka; Frank J Gonzalez
Journal:  J Lipid Res       Date:  2012-06-04       Impact factor: 5.922

2.  A Molecular Code for Identity in the Vomeronasal System.

Authors:  Xiaoyan Fu; Yuetian Yan; Pei S Xu; Ilan Geerlof-Vidavsky; Wongi Chong; Michael L Gross; Timothy E Holy
Journal:  Cell       Date:  2015-10-01       Impact factor: 41.582

3.  Role of fibroblast growth factor 21 in the early stage of NASH induced by methionine- and choline-deficient diet.

Authors:  Naoki Tanaka; Shogo Takahashi; Yuan Zhang; Kristopher W Krausz; Philip B Smith; Andrew D Patterson; Frank J Gonzalez
Journal:  Biochim Biophys Acta       Date:  2015-02-28

Review 4.  Potential role of CYP1B1 in the development and treatment of metabolic diseases.

Authors:  Fei Li; Weifeng Zhu; Frank J Gonzalez
Journal:  Pharmacol Ther       Date:  2017-03-16       Impact factor: 12.310

5.  Mitohormesis in Mice via Sustained Basal Activation of Mitochondrial and Antioxidant Signaling.

Authors:  Carly S Cox; Sharen E McKay; Marissa A Holmbeck; Brooke E Christian; Andrew C Scortea; Annie J Tsay; Laura E Newman; Gerald S Shadel
Journal:  Cell Metab       Date:  2018-08-16       Impact factor: 27.287

6.  Peroxisome proliferator-activated receptor alpha target genes.

Authors:  Maryam Rakhshandehroo; Bianca Knoch; Michael Müller; Sander Kersten
Journal:  PPAR Res       Date:  2010-09-26       Impact factor: 4.964

7.  FGF21 mediates the lipid metabolism response to amino acid starvation.

Authors:  Ana Luísa De Sousa-Coelho; Joana Relat; Elayne Hondares; Albert Pérez-Martí; Francesc Ribas; Francesc Villarroya; Pedro F Marrero; Diego Haro
Journal:  J Lipid Res       Date:  2013-05-09       Impact factor: 5.922

8.  Irisin Is Regulated by CAR in Liver and Is a Mediator of Hepatic Glucose and Lipid Metabolism.

Authors:  Li Mo; Jing Shen; Qinhui Liu; Yuwei Zhang; Jiangying Kuang; Shiyun Pu; Shihai Cheng; Min Zou; Wei Jiang; Changtao Jiang; Aijuan Qu; Jinhan He
Journal:  Mol Endocrinol       Date:  2016-03-23

Review 9.  Metabolomics: an essential tool to understand the function of peroxisome proliferator-activated receptor alpha.

Authors:  Jessica E Montanez; Jeffrey M Peters; Jared B Correll; Frank J Gonzalez; Andrew D Patterson
Journal:  Toxicol Pathol       Date:  2012-11-28       Impact factor: 1.902

10.  Applications of metabolomics for understanding the action of peroxisome proliferator-activated receptors (PPARs) in diabetes, obesity and cancer.

Authors:  Zsuzsanna Ament; Mojgan Masoodi; Julian L Griffin
Journal:  Genome Med       Date:  2012-04-30       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.